Preview Mode Links will not work in preview mode

Medscape InDiscussion: Schizophrenia

Mar 22, 2023

Drs John M. Kane and Jose Rubio-Lorente discuss the value of long-acting injectable formulations in reducing the risk for relapse and rehospitalization for patients diagnosed with schizophrenia.

Relevant disclosures can be found with the episode show notes on Medscape ( The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.



The Nature of Relapse in Schizophrenia

What Is the Risk-Benefit Ratio of Long-term Antipsychotic Treatment in People With Schizophrenia?

Long-Acting Antipsychotic Therapies for Patients With Schizophrenia

Long-term Continuity of Antipsychotic Treatment for Schizophrenia: A Nationwide Study

Predictors for Initiation of Atypical Long-Acting Injectable Antipsychotic Agents in a Commercial Claims Cohort of Individuals With Early-Phase Schizophrenia

Long-Acting Injectable Versus Oral Antipsychotics in Schizophrenia: A Systematic Review and Meta-analysis of Mirror-Image Studies

Antipsychotic Use Among Persons With Schizophrenia in Sweden and Finland, Trends and Differences

Predictors of Lack of Relapse After Random Discontinuation of Oral and Long-Acting Injectable Antipsychotics in Clinically Stabilized Patients With Schizophrenia: A Re-analysis of Individual Participant Data